Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 17:2021:2782875.
doi: 10.1155/2021/2782875. eCollection 2021.

Clinical Efficacy of Fuzheng Guben Anticancer Decoction Combined with Taxol in Treating Ovarian Carcinoma and Its Effect on Complication Incidence

Pinger Li  1 , Yinmei Lou  1
Affiliations

Clinical Efficacy of Fuzheng Guben Anticancer Decoction Combined with Taxol in Treating Ovarian Carcinoma and Its Effect on Complication Incidence

Pinger Li et al. Evid Based Complement Alternat Med. .

Abstract

Objective: To investigate the clinical value of Fuzheng Guben anticancer decoction combined with taxol in treating ovarian carcinoma (OC).

Methods: The medical records of 80 OC patients treated in the First People's Hospital of Fuyang Hangzhou (January 2018-January 2021) were retrospectively analyzed, and the patients were split into the control group and the experimental group according to the treatment regimen, with 40 cases each. Those in the control group accepted the taxol chemotherapy, and on this basis, those in the experimental group took the Fuzheng Guben anticancer decoction, so as to compare its clinical efficacy and complication incidence.

Results: No statistical between-group differences in patients' general information were observed (P > 0.05); compared with the control group, the disease objective remission rate of the experimental group was greatly higher (P < 0.05); before and after treatment, the changes in CD8+ were not significant, indicating no statistically significant between-group differences (P > 0.05), and after treatment, CD3+, CD4+, and CD4+/CD8+ were obviously higher than before and were obviously higher in the experimental group than in the control group (P < 0.05); after treatment, the CA125, CA199, and CEA levels were obviously lower than before and were significantly lower in the experimental group than in the control group (P < 0.05); the mean survival of the experimental group was significantly higher than that of the control group (19.80 ± 5.84 vs. 14.075 ± 5.12 months, P < 0.05); and between the two groups, the incidence rate of adverse reactions of the experimental group was remarkably lower (P < 0.05).

Conclusion: On the basis of taxol chemotherapy, jointly applying Fuzheng Guben anticancer decoction can significantly improve the clinical efficacy of OC, help to improve patients' immune function, lower the complication incidence rate, and prolong the mean survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Between-group comparison of clinical efficacy. Note: the horizontal axis showed the evaluation dimensions, and the vertical axis showed the percentage. In the control group, there were 15 CR cases, 14 PR cases, 7 SD cases, and 4 PD cases, so the number of ORR cases was 29. In the experimental group, there were 20 CR cases, 16 PR cases, 3 SD cases, and 1 PD case, so the number of ORR cases was 36; ∗ indicated a significant between-group difference in ORR (X2 = 4.021, P=0.045).
Figure 2
Figure 2
Survival curves.
See this image and copyright information in PMC

References

    1. Cai L., Xu G., Shi C., Guo D., Wang X., Luo J. Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: a synergistic combination nanotherapy for ovarian cancer treatment. Biomaterials . 2015;37:456–468. - PMC - PubMed
    1. Matulonis U. A., Sill M. W., Makker V., et al. A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology . 2019;152(3):548–553. doi: 10.1016/j.ygyno.2018.12.008. - DOI - PMC - PubMed
    1. Yao H., Ma J. Dendrimer-paclitaxel complexes for efficient treatment in ovarian cancer: study on OVCAR-3 and HEK293T cells. Acta Biochimica Polonica . 2018;65(2):219–225. - PubMed
    1. Ye H., Liu X. J., Hui Y., Liang Y. H., Li C. H., Wan Q. USF1 gene polymorphisms may associate with the efficacy and safety of chemotherapy based on paclitaxel and prognosis in the treatment of ovarian cancer. Neoplasma: Journal of Experimental and Clinical Oncology . 2018;65(1):153–160. doi: 10.4149/neo_2018_170322n205. - DOI - PubMed
    1. Guo L., Zhang S., Chen C., Zeng H., Li F., Xu Q. Lentinan combined with cisplatin and paclitaxel in the treatment of patients with ovarian cancer with ascites. European Journal of Gynaecological Oncology . 2018;39(4):615–620.